23 February 2026
23 February 2026
Synicem hold CE marking and full regulatory approval for use in the UK.
At week 140, 80.8% of those administered guselkumab achieved clinical remission.
The FDA decision is anticipated by 18 December 2026.
The NanoKnife system employs non-thermal IRE ablation to destroy tumour cells while preserving surrounding anatomy.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
